| Myasthenia Gravis, Generalized
Vyvgart Hytrulo vs Soliris
Side-by-side clinical, coverage, and cost comparison for myasthenia gravis, generalized.Deep comparison between: Vyvgart Hytrulo vs Soliris with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSoliris has a higher rate of injection site reactions vs Vyvgart Hytrulo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Soliris but not Vyvgart Hytrulo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Vyvgart Hytrulo
Soliris
At A Glance
SC injection
Once weekly
FcRn blocker
IV infusion
Every 2 weeks
Complement C5 inhibitor
Indications
- Myasthenia Gravis, Generalized
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Paroxysmal nocturnal hemoglobinuria
- Atypical Hemolytic Uremic Syndrome
- Myasthenia Gravis, Generalized
- Neuromyelitis Optica
Dosing
Myasthenia Gravis, Generalized 1,000 mg efgartigimod alfa/10,000 units hyaluronidase SC once weekly for 4-week cycles (prefilled syringe over 20-30 seconds) or 1,008 mg/11,200 units (vial over 30-90 seconds); subsequent cycles based on clinical evaluation.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating 1,000 mg efgartigimod alfa/10,000 units hyaluronidase SC once weekly (prefilled syringe over 20-30 seconds) or 1,008 mg/11,200 units (vial over 30-90 seconds); continue based on clinical response.
Paroxysmal nocturnal hemoglobinuria 600 mg IV infusion weekly for 4 weeks, then 900 mg at week 5, then 900 mg every 2 weeks thereafter.
Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis, Generalized, Neuromyelitis Optica (adults) 900 mg IV infusion weekly for 4 weeks, then 1200 mg at week 5, then 1200 mg every 2 weeks thereafter.
Atypical Hemolytic Uremic Syndrome, Myasthenia Gravis, Generalized (pediatric) Weight-based IV infusion dosing; induction and maintenance doses vary by body weight (5 kg to >=40 kg), administered every 2 to 3 weeks after induction.
Contraindications
- Serious hypersensitivity to efgartigimod alfa products, hyaluronidase, or any excipient of VYVGART HYTRULO (including anaphylaxis and hypotension leading to syncope)
- Unresolved serious Neisseria meningitidis infection
Adverse Reactions
Most common (>=10%) Injection site reactions (rash, erythema, pruritus, bruising, pain, urticaria), headache
Serious Infections, hypersensitivity reactions (including anaphylaxis and hypotension), infusion/injection-related reactions
Postmarketing Hypersensitivity reactions including anaphylaxis and hypotension, infusion/injection-related reactions, worsening of CIDP symptoms when transitioning from intravenous immunoglobulin treatment
Most common (>=5%) Headache, nasopharyngitis, back pain, nausea, fatigue, cough, herpes simplex infections, sinusitis, upper respiratory tract infection, diarrhea, vomiting, hypertension, musculoskeletal pain, abdominal pain, peripheral edema, pyrexia, arthralgia, influenza, contusion
Serious Meningococcal infections, other serious infections, disease exacerbation after SOLIRIS discontinuation, thrombosis, infusion-related reactions
Postmarketing Fatal or serious infections (Neisseria gonorrhoeae, Neisseria meningitidis, Neisseria sicca/subflava, Neisseria spp unspecified), cholestatic or mixed pattern liver injury in aHUS patients
Pharmacology
Efgartigimod alfa, a human IgG1 Fc fragment, binds to the neonatal Fc receptor (FcRn) and reduces circulating IgG; co-formulated hyaluronidase transiently depolymerizes hyaluronan to increase subcutaneous tissue permeability for 24 to 48 hours.
Eculizumab is a monoclonal antibody that specifically binds complement protein C5 with high affinity, inhibiting its cleavage to C5a and C5b and preventing generation of the terminal complement complex C5b-9, thereby inhibiting terminal complement-mediated intravascular hemolysis in PNH, complement-mediated thrombotic microangiopathy in aHUS, and presumed reduction of terminal complement C5b-9 deposition at the neuromuscular junction in gMG and in NMOSD.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Vyvgart Hytrulo
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
Soliris
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (9/12)
UnitedHealthcare
Vyvgart Hytrulo
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (0/8)
Soliris
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Vyvgart Hytrulo
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Soliris
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Vyvgart Hytrulo.
No savings programs available for Soliris.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Vyvgart HytruloView full Vyvgart Hytrulo profile
SolirisView full Soliris profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.